Experimentation and Validation Questions

Hypothesis:

• Primary: Providing standardized Solutions Architecture (SA) interventions (templates + reference architectures + prebuilt collateral) reduces average sales cycle time and increases win rate compared to current ad-hoc SA support.

Experiment design:

• Unit of randomization: sales opportunity (deal) stratified by segment (ARR band), product, and region.
• Experimental group: opportunities where AE + SA must use the standardized kit (template, reference architecture, checklist, 1-hour templated workshop).
• Control group: opportunites receive “business-as-usual” SA support.

Sample size considerations:

• Determine minimum detectable effect (MDE): e.g., 10% reduction in cycle time and 5 percentage-point lift in win rate. Use historical mean cycle time and win rate, desired power 80%, alpha 0.05. For win rate (binary) apply two-proportion sample size; for cycle time (continuous, often right-skewed) use log-transform — compute n per arm accordingly and inflate for expected loss-to-follow-up.

Key metrics:

• Primary: time from opportunity creation → closed-won/closed-lost (median & mean), win rate (closed-won / closed-decisions).
• Secondary: time to first technical deliverable, number of SA touchpoints, proposal rework rate, deal size (ACV), customer satisfaction (post-win NPS).
• Safety/quality: % of technical escalations post-close.

Analysis approach:

• Pre-specify primary endpoints and analysis window.
• For win rate: two-proportion z-test or logistic regression (adjusted for stratification covariates) to estimate odds ratio and adjusted risk difference.
• For cycle time: compare log-transformed times using t-test or linear regression; report geometric means and median differences via nonparametric tests (Wilcoxon) if skewed.
• Use survival analysis (Kaplan-Meier + Cox proportional hazards) to handle censored opportunities (still open at analysis cutoff).
• Adjust for multiplicity if testing both endpoints (e.g., hierarchical testing or Bonferroni).
• Report effect sizes, 95% CIs, and p-values. Conduct subgroup analyses (enterprise vs. SMB) pre-specified.

Potential confounders and mitigations:

• Deal complexity, salesperson skill, seasonality, marketing campaigns, pricing changes, product roadmap shifts. Mitigate via stratified randomization, regression adjustment, and blocking by time windows.
• Contamination: SAs learning templates and applying to control deals—mitigate by clear assignment rules, logging SA actions, and possibly cluster-randomizing by SA for a sensitivity analysis.
• Selection bias: ensure randomization occurs at opportunity creation and is enforced by CRM hooks.
• Operational constraints: run long enough to capture sales cycles across segments; monitor interim metrics but avoid peeking without pre-specified stopping rules.

Interpretation:

• Combine statistical and practical significance: even modest win-rate lifts at scale can justify adoption if quality metrics remain stable.
• If positive, plan rollout with training, feedback loop, and A/B follow-ups for iterative improvements.

Goal: run a fast, low-risk experiment that directly compares Instrumental Variable (IV) estimation vs. Randomized Controlled Trial (RCT) estimates for the same personalization treatment to resolve whether IV delivers comparable causal estimates for our product.

Hypothesis

• H0: IV estimate of ATE for the personalization rule differs from RCT estimate by more than the Minimum Detectable Effect (MDE) threshold.
• H1: IV estimate and RCT estimate are statistically equivalent within MDE.

Primary metrics

• Treatment effect on key business metric: 7-day conversion rate (binary) and secondary: average revenue per user (ARPU) over 7 days.
• For comparability: difference Δ = IV_estimate - RCT_estimate, with equivalence bounds ±MDE.

MDE & power

• Business decides MDE = 1.5 percentage points (ppt) on conversion (clinically meaningful).
• Power 80%, alpha 0.05, two-sided equivalence test.
• Baseline conversion p0 = 8%. Using pooled variance for difference-in-differences, approximate sample per arm:
  n ≈ 2 * (Z_{1-α/2}+Z_{1-β})^2 * p0(1-p0) / MDE^2
  With Zs = 1.96+0.84=2.8 → n ≈ 2*(2.8^2)0.080.92/0.015^2 ≈ 27.840.0736/0.000225 ≈ (1.155)/0.000225 ≈ ~5,133 → per arm ~5.5k users. Add 20% to cover attrition → ~6.6k per arm.
• Design needs three groups: RCT-control, RCT-treatment, IV-instrumented (encouragement) — so total ~20k users.

Experiment design & timeline

• Week 0: finalize instrumentation, data schema, and analysis plan (pre-registration).
• Week 1: deploy feature flags and instrument (IV encouragement) in a 1–2% user slice (pilot).
• Weeks 2–3: run full roll for 14 days (captures short-term conversions).
• Week 4: QA, run pre-registered analyses, sensitivity checks, and publish.

Concrete experimental architecture & logging

• Routing layer: feature-flag service assigns users into three buckets using stratified hashing (by region, device).
• RCT arm: deterministic RNG to assign treatment exposure.
• IV arm: randomized encouragement instrument (e.g., push notification or UI nudge) that increases probability of treatment; record instrument assignment, actual treatment receipt, and compliance indicator.
• Logging: user_id (hashed), bucket_id, instrument_assignment, treatment_exposure_timestamp, treatment_variant, conversion_flag, revenue, covariates (prior activity, device, region), timestamp, experiment_version.
• Ensure idempotent events, consistent user keys, and privacy-preserving hashing.

Analysis plan

• RCT: estimate ATE using intent-to-treat (ITT) and per-protocol; compute standard errors.
• IV: use two-stage least squares (2SLS) with instrument → treatment → outcome; report local average treatment effect (LATE), first-stage F-stat (>10), weak instrument checks.
• Compare estimates by computing Δ and 95% CI; run equivalence test (two one-sided tests) against ±MDE.
• Sensitivity: subgroup analyses (device, geography), placebo outcomes, and covariate-adjusted models.

How to present results to both teams

• Executive slide (concise): question, design diagram, sample size, primary result (Δ, CI), equivalence verdict, business implication.
• Technical appendix for engineers & data scientists: data schema, randomization code, logs sample, first-stage diagnostics, regression specs, robustness checks, and reproducible notebooks.
• Joint debrief session: walk through architecture, demonstrate reproducibility, discuss trade-offs (IV gives LATE under complier population; RCT gives ITT; external validity differences), recommended path depending on results (if equivalent → IV usable when RCT infeasible; if not → prefer RCT or refine instrument).

Risk & trade-offs

• IV measures LATE — clarify population. Weak instrument risk mitigated by strong encouragement design and first-stage checks.
• Short timeline favors 2-week exposure; for long-term outcomes extend duration.
• Operational: isolate experiment slice to avoid cross-contamination; rollbacks ready.

This experiment yields a direct numeric comparison, technical diagnostics, and clear guidance for when each method is acceptable for personalization decisions.

Primary metric (primary KPI):

• Average end-to-end latency for API calls (ms) weighted by call volume — lower is better.
  Secondary metrics:
• Wire cost per call and total wire egress cost ($) — lower is better.
• Cache hit rate (%), backend request rate (requests/sec).
• Error rate (4xx/5xx) and tail latency (p95/p99).
• Business/functional correctness: fraction of stale or inconsistent responses.
  Experiment design:
• Randomized A/B at request or client-session level depending on routing ability. Treatment: requests go through cache (with TTL/configured policy). Control: current baseline (no cache).
  Sample size & duration:
• Compute sample size to detect a minimal meaningful latency reduction (e.g., 10% mean) with power 80% and alpha 0.05. Use historical latency variance to estimate n; if unavailable, run a 2-week pilot to estimate variance. Ensure capturing weekly traffic cycles; typical duration = 2–4 weeks.
  Traffic split:
• Start 90/10 (control/treatment) for safety, then move to 50/50 when stable.
  Confounders to watch:
• Traffic seasonality, deployment or infra changes, client-side retries, differing request mixes (heavy vs light payloads) between groups, CDN effects, backend autoscaling thresholds.
  Instrumentation:
• Tag metrics by cohort. Log origin (cache vs origin) for each response, TTL state, and consistency checks for a sample of responses.
  Success criteria:
• Statistically significant reduction in primary metric (e.g., p < 0.05) and material wire cost savings (e.g., >X% or $Y/month) without an increase in error rate or stale-response rate beyond SLA.
  Rollback criteria:
• Any statistically significant increase in errors, p99 latency regression, customer-facing correctness issues, or unexpected backend load patterns. Also rollback if cache introduces > acceptable inconsistency or if cache instability (eviction storms) is observed.
  Post-experiment:
• Run segmentation analysis (by endpoint, client, payload size). If positive, plan phased rollout with monitoring, TTL tuning, and cache warming. Document trade-offs and update architecture diagrams and runbooks.

A) Technical-level (CTO)
Netflix uses a modular experimentation stack that separates control plane (experiment definition & targeting) from data plane (metrics collection & analysis) and the runtime (feature delivery & rollout).

Architecture components:

• Experimentation platform: authoring UI + API where engineers/product define variants, sample ratios, targeting rules, and duration. Stores experiment metadata and enforces assignment consistency.
• Feature-flag / rollout service: low-latency SDKs in clients/servers evaluate flags locally using deterministic user bucketing (hashed IDs) and exposure logging; supports staged rollouts, kill-switch, and config overrides.
• Metrics pipeline: high-throughput event ingestion (streaming) → enrichment → denormalized metrics store for near-real-time dashboards. Events include exposures, conversions, and diagnostics.
• Analysis engine: batch/stream statistical engine applying sequential testing corrections, Bayesian or frequentist models, automated A/A checks, and false-discovery controls. Produces significance, MDE, uplift and power reports.
• Monitoring & safety: anomaly detection, automated guardrails (SLO/health monitors), canary jobs, and automatic rollback triggers integrated with deployment pipelines.
  Data flow: define experiment → SDK assigns bucket & logs exposure → events flow to metrics pipeline → analysis engine computes results → rollout service uses outcomes to ramp or rollback.

B) Product-level (PM)
Think of it as a safe way to test ideas on real users with measurable business impact and minimal risk.

How it works:

• You design an experiment: who sees it, what the variants are, and which KPIs matter (primary metric + safety metrics like playback error rate).
• A feature-flag system delivers the variant to a randomized sample of users and lets you ramp exposure gradually (1% → 10% → 50%).
• Real-time metric collection and dashboards show effect on your primary metric and guardrail metrics. Automated checks flag anomalies.
• Statistical analysis tells you whether observed differences are meaningful (confidence, minimum detectable effect) and recommends when to stop, ramp, or roll back.
  Safety & impact controls:
• Start small with canaries, monitor health metrics continuously, have kill-switches and rollbacks automated, and require predefined success criteria before full rollout.
  Outcome focus:
• You get quantified lift (or harm) with clear confidence, and the platform enforces safety so you can move quickly without endangering core user experience.

Approach: Treat this as an end-to-end A/B experiment — define clear success criteria, ensure statistical rigor, and design the implementation so Engineering can safely deploy, measure, and roll back.

Primary & secondary metrics

• Primary metric: one business-focused, leading indicator tied to the feature goal. Example: “Conversion rate from trial to paid within 14 days” or “task completion rate.” Must be a single metric for hypothesis testing.
• Secondary metrics: safety and health signals (error rate, latency, CPU), engagement (time-on-task, DAU), downstream business KPIs (retention, revenue per user). Include uplift/downgrade thresholds to detect harm.

Sample size & duration

• Compute sample size using baseline conversion p0, minimum detectable effect (MDE, e.g., 5%), alpha=0.05, power=0.8. Use standard two-proportion formulas or an online calculator.
• Set duration to cover at least one full business cycle and account for user behavior periodicity (min 2–4 weeks for consumer; can be longer for low-traffic B2B). Ensure enough unique users, not sessions.

Rollout criteria

• Success: statistically significant improvement on primary metric and no degradation on safety metrics; secondary metrics within defined bounds.
• Stop/rollback rules: statistically significant harm on primary or any safety metric exceeds threshold (e.g., >2x baseline error rate), or infra limits reached.
• Progressive ramp: start with small percent (1–5%) -> canary (10–25%) -> full sample once checks pass.

Engineering collaboration

• Instrumentation: define event schema, naming, and dimensions (user-id, cohort, timestamp, variant). Use idempotent, strongly-typed telemetry events and include sampling flags.
• Measurement pipeline: ensure events flow to analytics (streaming and batch), validate data quality with smoke queries and backfills.
• Feature-flag design: implement server-side flag with kill-switch and rollout percentage; tie flag state to audit logs and deploy controls.
• Safety: add circuit-breakers, rate-limits, health checks, and observability dashboards (latency, error-rate, resource usage) before ramp.
• Reproducibility: log cohort assignment and seed so users are consistently bucketed; provide exportable datasets for stats team.
• Verification: run an experiment readiness checklist (event counts per cohort, schema validation, end-to-end test) before opening traffic.
• Communication: document success criteria, sample-size calc, rollback plan, and runbook; schedule a post-mortem and metric dashboard for real-time monitoring.

This ensures the experiment is statistically sound, measurable, safe to roll back, and engineered for reliable instrumentation and observability.